172 related articles for article (PubMed ID: 35268755)
1. Rational Design and Synthesis of HSF1-PROTACs for Anticancer Drug Development.
Sharma C; Choi MA; Song Y; Seo YH
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268755
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src.
Manda S; Lee NK; Oh DC; Lee J
Molecules; 2020 Apr; 25(8):. PubMed ID: 32340152
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
4. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
5. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
6. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis-targeting chimeras with reduced off-targets.
Nguyen TM; Sreekanth V; Deb A; Kokkonda P; Tiwari PK; Donovan KA; Shoba V; Chaudhary SK; Mercer JAM; Lai S; Sadagopan A; Jan M; Fischer ES; Liu DR; Ebert BL; Choudhary A
Nat Chem; 2024 Feb; 16(2):218-228. PubMed ID: 38110475
[TBL] [Abstract][Full Text] [Related]
8. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
9. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
11. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
12. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
13. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of PROTACs.
Benowitz AB; Jones KL; Harling JD
Expert Opin Ther Pat; 2021 Jan; 31(1):1-24. PubMed ID: 33081540
[TBL] [Abstract][Full Text] [Related]
15. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
[TBL] [Abstract][Full Text] [Related]
16. Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues.
Shi S; Du Y; Zou Y; Niu J; Cai Z; Wang X; Qiu F; Ding Y; Yang G; Wu Y; Xu Y; Zhu Q
J Med Chem; 2022 Mar; 65(6):5057-5071. PubMed ID: 35175763
[TBL] [Abstract][Full Text] [Related]
17. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.
Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
